Walvax Biotechnology Co., Ltd.

¥11.45As of Sun 8 Nov 2026, 12:00 UTC
SZSE:300142Healthcare
Country China
PE (Fwd) •••
TSR 10Y CAGR 1.51%
Div yield 1.35%
ROE 0.20%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.74
PE TTM 840.7
TSR TTM (5.18%)
Mkt cap ¥18.31B
ROIC 0.43%
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥15
27.04%
(7.16%)
Hold 7|6|1|6|4
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.13
0.12
0.13
0.12
11.98%
8.99%
13.02%
3.23%
Revenue¥M
951.0
949.0
981.1
976.7
(4.76%)
(3.94%)
0.18%
2.52%
Peers (US$2.745B)
Cap (US$)
PE
2.744B
40.61x
Capital
TTM
5Y
10Y
Leveragex
3.809
9.361
7.947
EBIT/Intx
0.767
0.204
0.221
Own earn%
(258.80)
16.12
14.14
Sh yield%
53.10
39.85
35.27
Owners
Insiders/Inst%
10.41
81.93
Short interest%
1.06
SBC / revenue%
4.82
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
30–36
$1 testx
—
Incr. ROIC%
7